Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BT-474 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 0.000219 | uM | 9158.123 | 0.9104 | 0.7970 | 0.8769 | |
| BT-474 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 0.0011 | uM | 9158.123 | 0.9468 | 0.8792 | 0.8769 | |
| BT-474 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 0.00548 | uM | 9158.123 | 0.9185 | 0.8153 | 0.8769 | |
| BT-474 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 0.0274 | uM | 9158.123 | 0.9403 | 0.8644 | 0.8769 | |
| BT-474 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 0.137 | uM | 9158.123 | 1.0181 | 1.0413 | 0.8769 | |
| BT-474 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 0.685 | uM | 9158.123 | 0.8944 | 0.7610 | 0.8769 | |
| BT-474 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 0.00000175 | uM | 9163.026 | 1.0046 | 1.0246 | 0.3738 | |
| BT-474 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 0.00000877 | uM | 9163.026 | 1.0119 | 1.0643 | 0.3738 | |
| BT-474 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 0.0000438 | uM | 9163.026 | 0.9595 | 0.7905 | 0.3738 | |
| BT-474 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 0.000219 | uM | 9163.026 | 0.9801 | 0.8954 | 0.3738 | |
| BT-474 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 0.0011 | uM | 9163.026 | 0.9819 | 0.9045 | 0.3738 | |
| BT-474 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 0.00548 | uM | 9163.026 | 0.9911 | 0.9527 | 0.3738 | |
| BT-474 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 0.0274 | uM | 9163.026 | 0.9784 | 0.8867 | 0.3738 | |
| BT-474 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 0.137 | uM | 9163.026 | 0.9870 | 0.9313 | 0.3738 | |
| BT-474 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 0.685 | uM | 9163.026 | 0.9638 | 0.8122 | 0.3738 | |
| BT-483 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.00000175 | uM | 7801.018 | 0.9888 | 0.9622 | 0.5913 | |
| BT-483 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.00000877 | uM | 7801.018 | 0.9565 | 0.8549 | 0.5913 | |
| BT-483 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.0000438 | uM | 7801.018 | 1.0011 | 1.0036 | 0.5913 | |
| BT-483 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.000219 | uM | 7801.018 | 0.9502 | 0.8345 | 0.5913 | |
| BT-483 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.0011 | uM | 7801.018 | 0.9397 | 0.8004 | 0.5913 | |
| BT-483 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.00548 | uM | 7801.018 | 0.9534 | 0.8448 | 0.5913 | |
| BT-483 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.0274 | uM | 7801.018 | 1.0464 | 1.1594 | 0.5913 | |
| BT-483 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.137 | uM | 7801.018 | 0.9731 | 0.9099 | 0.5913 | |
| BT-483 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.685 | uM | 7801.018 | 0.9251 | 0.7533 | 0.5913 | |
| BT-483 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.00000175 | uM | 9186.026 | 1.1176 | 1.4864 | 0.5108 |